Need help finding what you are looking for?
Contact Us
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084699
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084699
Vernal Keratoconjunctivitis Market, By Drug Type, By Treatment, By Dosage Form, By Distribution Channel, By Geography
PUBLISHED:
PAGES: 259 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Vernal Keratoconjunctivitis Market is estimated to be valued at USD 414.0 Mn in 2026 and is expected to reach USD 530.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 414.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.60% | 2033 Value Projection: | USD 530.3 Mn |
The inner surface of the eyelid is lined with conjunctiva, a translucent tissue layer. When infected, this tissue tends to cover the white area of the eye and turn red or pink. As a result, the eye ailment conjunctivitis is often known as pink eye. The infection of the eye known as conjunctivitis is a common symptom of this ophthalmic condition. Infectious causes includes bacterial and viral infections, while non-infectious causes include allergy and immune-mediated illness inflammation. It is categorised into acute conjunctivitis, super acute conjunctivitis, and chronic conjunctivitis.
Vernal keratoconjunctivitis (VKC) is a chronic, multifactorial Th2-cell-mediated inflammatory disease of the ocular surface. It is distinguished by a large papilla on the upper tarsal conjunctiva and a corneoscleral junction. Hyperemia and mucus discharge are typical symptoms of VKC. There is no set standard treatment strategy for VKC. Mast cell stabilisers, antihistamines, nonsteroidal anti-inflammatory medications (NSAIDs), topical corticosteroids, and cyclosporine are available as treatments. Individuals receiving treatment should be continuously observed for the development of any ocular problems.
Market Dynamics
Increasing R&D activities in vernal keratoconjunctivitis for a better understanding of the disease is expected to drive the growth of global vernal keratoconjunctivitis market during the forecast period. In addition, increasing prevalence of vernal keratoconjuctivitis and supportive therapies have built the interest in several pharmaceutical companies in developing a cure for the disease. A greater knowledge of the disease's biology and manifestation of the disease has boosted efforts to develop improved treatment alternatives in the form of pipeline treatments, which is projected to propel the global vernal keratoconjunctivitis market share during the forecast period.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global vernal keratoconjunctivitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
- Key companies covered as a part of this study include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global vernal keratoconjunctivitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global vernal keratoconjunctivitis market
Market Segmentation
- By Drug Type (Revenue, USD Mn, 2021-2033)
- Bertilimumab
- Verkazia
- Lodoxamide
- Tacrolimus
- Antolimab
- Nomacopan
- Others
- By Treatment (Revenue, USD Mn, 2021-2033)
- Mast Cell Stabilizers
- Antihistamines
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Topical Corticosteroids
- Cyclosporine
- Tacrolimus
- Others
- By Dosage Form (Revenue, USD Mn, 2021-2033)
- Gel
- Ointment
- Tablet
- Others
- By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Region (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Santen
- Novartis Pharmaceuticals
- Senju Pharmaceutical
- Allakos
- iCo Therapeutics
- Akari Therapeutics
Product Code: CMI4657
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Treatment
- Market Snapshot, By Dosage Form
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Vernal Keratoconjunctivitis Market, By Drug Type, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Bertilimumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Verkazia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Lodoxamide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Tacrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Antolimab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Nomacopan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
5. Global Vernal Keratoconjunctivitis Market, By Treatment, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Mast Cell Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Antihistamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Topical Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Cyclosporine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Tacrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
6. Global Vernal Keratoconjunctivitis Market, By Dosage Form, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Gel
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Ointment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
7. Global Vernal Keratoconjunctivitis Market, By Distribution Channel, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
8. Global Vernal Keratoconjunctivitis Market, By Region, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Santen
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Senju Pharmaceutical
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Allakos
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- iCo Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Akari Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Santen
- Analyst Views
10. Section
- References
- Research Methodology
- About Us
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.